By using Glunomab, an antibody that prevents NMDAR1 interaction with tPA without disrupting NMDAR1 ion channel function, we identified a potential therapeutic approach to inhibit tPA-mediated neuroinflammation and neurodegeneration in PD. This evidence concerns the gene GRIN1 and Parkinson disease.